# COVID-19 FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/covid-19

> No upcoming FDA catalysts in COVID-19; 7 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for COVID-19?

No upcoming FDA catalysts in COVID-19; 7 past events are recorded. ClinicalTrials.gov: "NCT07655180 (Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-15 (ACTUAL); Lead Sponsor Invivyd, Inc.." [Calendar and source filings](https://sec-api.dev/indications/covid-19)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT07655180 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/covid-19#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 24, 2025 | [Cic vaccine co-formulated tniv2 , sarscov-2 rs and matrix-m adjuvant primary completion](https://sec-api.dev/pdufa/cic-vaccine-co-formulated-tniv2-sarscov-2-rs-and-matrix-m-adjuvant) | NVAX | COVID-19 | completed | "NCT06291857 (A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-24 (ACTUAL); Lead Sponsor Novavax." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06291857)) |
| February 16, 2026 | [Ratutrelvir (83-0060) non-randomised primary completion](https://sec-api.dev/pdufa/ratutrelvir-83-0060-non-randomised) | TRAW | COVID - 19 | completed | "NCT07157007 (Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-16 (ACTUAL); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157007)) |
| Q3 2026 | [VYD2311 topline data readout](https://sec-api.dev/pdufa/vyd2311) | IVVD | COVID-19 | scheduled | "Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which top-line data is anticipated in Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex991.htm)) |
| July 2026 | [Nirmatrelvir primary completion](https://sec-api.dev/pdufa/nirmatrelvir) | PFE | COVID-19 | delayed | "NCT05261139 (EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-07-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05261139)) |
| August 2026 | [VYD2311-SD primary completion](https://sec-api.dev/pdufa/vyd2311-sd) | IVVD | COVID-19 | delayed | "NCT07298434 (Study of VYD2311 for the Prevention of COVID-19): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07298434)) |
| Aug to Nov 2026 | [VYD2311-SD topline data readout](https://sec-api.dev/pdufa/vyd2311-sd) | IVVD | COVID-19 | scheduled | "NCT07298434 (Study of VYD2311 for the Prevention of COVID-19): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07298434)) |
| August 15, 2026 | [VYD2311 primary completion](https://sec-api.dev/pdufa/vyd2311) | IVVD | COVID-19 | completed | "NCT07655180 (Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-15 (ACTUAL); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07655180)) |

## Drugs

- [Cic vaccine co-formulated tniv2 , sarscov-2 rs and matrix-m adjuvant](https://sec-api.dev/pdufa/cic-vaccine-co-formulated-tniv2-sarscov-2-rs-and-matrix-m-adjuvant) (NVAX)
- [Ratutrelvir (83-0060) non-randomised](https://sec-api.dev/pdufa/ratutrelvir-83-0060-non-randomised) (TRAW)
- [VYD2311](https://sec-api.dev/pdufa/vyd2311) (IVVD)
- [Nirmatrelvir](https://sec-api.dev/pdufa/nirmatrelvir) (PFE)
- [VYD2311-SD](https://sec-api.dev/pdufa/vyd2311-sd) (IVVD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/covid-19.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "COVID-19 FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/covid-19

```bibtex
@misc{secapidev_indications_covid_19_20261116,
  title        = {COVID-19 FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/covid-19}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_covid_19_20261116","title":"COVID-19 FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/covid-19","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
